• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Hidradenitis Suppurativa Companies

    ID: MRFR/Pharma/2497-HCR
    68 Pages
    Rahul Gotadki
    September 2025

    Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by the formation of painful nodules, abscesses, and tunnels under the skin, typically in areas where skin rubs together. While there is no cure for HS, various pharmaceutical companies are actively involved in researching and developing treatments to manage symptoms and improve the quality of life for individuals with this condition.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Hidradenitis Suppurativa Market Research Report - Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Hidradenitis Suppurativa Market

    Hidradenitis Suppurativa Key Companies

     

    Latest Hidradenitis Suppurativa Companies Update



    Positive Phase 3 results for bimekizumab (Sun Pharma): December 2023 saw promising news with BE HEARD I and II trials demonstrating significant improvements in pain and overall disease activity in HS patients treated with bimekizumab. This could lead to a new biologic option for moderate-to-severe HS.


    Secukinumab (Novartis) emerges as a leading treatment: October 2023 research confirms Secukinumab's increasing adoption by dermatologists, solidifying its position as a key player in the HS treatment landscape.


    AbbVie initiates Phase 2 trial for Upadacitinib: January 2024 news brings us another potential contender, with AbbVie investigating Upadacitinib, a JAK inhibitor, for HS treatment.


    FDA approves intravenous Cosentyx (Novartis) for HS: June 2023 approval offers a new administration option for this biologic, potentially improving convenience for some patients.


    List of Hidradenitis Suppurativa Key Companies in the Market




    • AstraZeneca (UK)




    • Pfizer Inc.(US)




    • GlaxoSmithKline plc. (UK)




    • Merck & Co., Inc. (US)




    • Johnson & Johnson Services Inc. (US)